Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers - Test2 - elhamkhani - TriplyDB

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

http://www.wikidata.org/entity/Q24654487

about

Challenging and complex decisions in the management of the BRCA mutation carrier Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.Personalized assessment and management of women at risk for breast cancer in North America Intensified surveillance for early detection of breast cancer in high-risk patients Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial.A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer Clinical management of hereditary breast cancer syndromes.DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct.Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011.The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.Online tool to guide decisions for BRCA1/2 mutation carriers.Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect".Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral.Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?Establishing a program for individuals at high risk for breast cancer.Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC)Experience with Bilateral Risk-Reducing Mastectomy for an Unaffected BRCA Mutation Carrier Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States.Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers.Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades.Management of acute cholecystitis in cancer patients: a comparative effectiveness approach.

P2860

Q27026559-264BCBB6-8216-4BC0-838B-A28BA268490D Q27316521-7A77ACEE-C25B-40D1-8A47-FC03D3CE704F Q28083876-F9023CDB-2FAE-49BD-93F6-5C0817E98B87 Q30392157-B8E9DCC2-6173-4DE0-993F-4551125BC589 Q31048641-65A43D93-5E8F-43E4-92DC-319BF3E89A94 Q33564013-AC114619-F88F-476A-857E-256C7A7CCEC2 Q33789533-723B08CE-716E-4D56-BB15-BF768636EE81 Q34001845-D39EAA5F-619C-4721-852F-3DA2150BCF61 Q34097351-C4E85475-2FBC-460D-B6D5-AE9459051D7F Q34152848-FE8D926C-B65C-4588-82F0-634BF8BF9996 Q34167563-5E5E5C35-A792-4017-909A-D90EAE027896 Q34262449-C86D1BCD-45EB-4106-B2E9-DF97557C9EB5 Q34436508-87D24DB5-496F-451A-A9BF-9E0748C5F97D Q34481713-AE9A6F45-55C5-46DA-BB4D-11F4A01B503A Q34663394-C521CB49-2678-4FA9-AFF1-BF6B5A1B7D11 Q34736052-2E63A1EF-B7F8-45D2-97E8-9888EA73AAB4 Q34803360-D4D4FD92-EDD7-448B-9610-3FD15E46DF03 Q35021170-DF810DFE-27D9-4F69-81C5-D8ABDD51A076 Q35687632-3775B895-376A-416D-A452-296AEF77C86F Q35808372-6DBCD3D6-D79B-407A-8664-A396D0C7CA5C Q36070986-65DA0E12-9EA3-4627-973D-2059D8565FF1 Q36117690-F7265182-BA10-4F9C-A511-A77771F307F1 Q36161162-FBD535A2-4097-41E4-805E-FBA158DF3CCC Q36218446-B3A896D5-A354-48AE-B79A-BC553460BC71 Q36406519-594F1D02-3E0B-4562-BEDC-F072258E0876 Q36595729-572B33EE-8E02-44FC-8C1C-314680D75E04 Q36634141-4D5E1DE9-38B5-4369-AA49-9039C24AA1CB Q36738628-9EE753F5-61F5-434A-A38F-F3809FBCFEBB Q36800313-19C94114-AF1B-4061-8EE0-CF87FDF2BB96 Q36906183-8CD41D08-96F3-4F5C-AB71-DB1F260D132B Q36918233-C0E693AE-C612-4F81-BE9D-211890201B37 Q36983389-7B7AA70B-A706-49F4-88F9-E4513C74FDDD Q37043791-08D78DF6-C063-4C95-A068-4B59BEB52F4F Q37056948-30CDFACB-BBEA-434D-8742-5406F35DEF46 Q37125021-C7AE7927-FEC9-4DB0-9917-11A93A4CFAE8 Q37450153-865BDA53-408D-499C-B050-13DF7D3755F8 Q37583113-6F303979-9024-4EBD-84FE-99230F7579F6 Q37994638-57AD2D8B-9BE0-4057-80A6-328B24E83DEA Q38159974-B34097E0-A6DE-4660-ACF5-F615913BD5B1 Q38200940-A863006A-C0E9-4BE1-AB75-39CE3C349088

P2860

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

http://www.wikidata.org/entity/Q24654487

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@ast

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@en

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@nl

type

label

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@ast

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@en

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@nl

prefLabel

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@ast

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@en

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@nl

P1433

Q24654487-3CDBB9F2-B66A-4897-8D22-7615D9E162F3

P1476

Q24654487-DC5A271D-168D-457F-A414-AECC6F0FF7CA

P2093

Q24654487-015941B5-D41D-45D1-9BD3-F3B66F416DBB

Q24654487-AF6F47F1-E216-4E41-8EBF-24DBD6E4902F

Q24654487-D1EF5E7E-79F5-41B0-BC18-650D8A280E09

P2860

Q24654487-01ACBB8B-D651-44DA-93C9-F6F3C64B5F77

Q24654487-07AA2A7B-080B-43A4-AAE2-AE43272459D9

Q24654487-0B831309-6DDE-41F7-B74B-FD8F749961EB

Q24654487-0CEEB728-C3F2-4614-821F-FA8B6F6B6B10

Q24654487-0E94CC8F-18DE-4372-9601-46CECD672272

Q24654487-0FAFB7BE-195D-4B2B-82A6-2DDA301D8618

Q24654487-0FF263F3-AE20-44FF-9A5B-A61049FF0EBF

Q24654487-143CD56B-4AD1-4748-BF56-8AAB9004B7F0

Q24654487-151A97F3-73E8-428F-BF14-ADD5FE8D39CA

Q24654487-17195FC1-5B0F-4C7C-8CB0-B1064031F435

P304

Q24654487-0B969DE6-3F01-4D1F-91F4-DA97980F0D34

P31

Q24654487-5A780A0B-3683-4366-BAA9-667AB503D17F

P3181

Q24654487-0C8F360B-EA69-4E49-9495-250DFED00EB6

P356

Q24654487-1AEC2A01-2158-4AA3-AF22-3EE9BE65D84C

P407

Q24654487-5755DDDF-508C-4CAF-8561-30638BBD3206

P433

Q24654487-D12A10A1-1879-452E-8039-5E3AA5B22F65

P478

Q24654487-C7D85FF9-A1DD-4A85-AEA1-7C4C6C5236B0

P577

Q24654487-F80ABE65-546A-4178-9680-4439EA3B9D6E

P5875

Q24654487-21F87DA7-7B52-40FB-8A9C-353C721A9760

P698

Q24654487-AE99389C-330C-4E1F-9FDB-2759ECA1834D

P932

Q24654487-99717094-63F5-4479-A774-B1F0DDAFCD10

P3181

P356

JCO.2009.22.7991

P1433

Journal of Clinical Oncology

P1476

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers

@en

P2093

Allison W Kurian

http://www.w3.org/2001/XMLSchema#string

Bronislava M Sigal

http://www.w3.org/2001/XMLSchema#string

Sylvia K Plevritis

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Meta-analysis of BRCA1 and BRCA2 penetrance

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage.

P304

222-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

160717

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2009.22.7991

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40482862

http://www.w3.org/2001/XMLSchema#string

P698

19996031

http://www.w3.org/2001/XMLSchema#string

P932

2815712

http://www.w3.org/2001/XMLSchema#string